Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Dashyant Dhanak"'
Publikováno v:
Cell chemical biology. 24(9)
Advances in understanding the role and molecular mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clinical practice in the treatment of cancer. Presently, multiple biologic drugs targeting the immune check
Autor:
Carol Thach, Jeff Kucharski, Jingchuan Zhang, Yvonne Yao, Shuangwei Li, Anjali Babbar, Dashyant Dhanak, Rasmus Hansen, Yuan Liu, Yuching Chen, Pingda Ren, Ulf Peters, Yi Liu, Shisheng Li, Ke Yu, Yi Wang, Patrick Parvis Zarrinkar, Xiaohu Deng, Matthew R. Janes, Sarah J. Firdaus, Ata Zarieh, Lian-Sheng Li, Tao Wu, Xin Guo, Jun Feng, Matthew V. Lorenzi, Dana D. Hu-Lowe, Jeffrey H. Chen
Publikováno v:
Cancer Research. 78:929-929
Activating mutations in KRAS have a high prevalence in human cancer. The codon 12 glycine to cysteine missense mutation (KRASG12C) is among the most common KRAS mutations, present in non-small cell lung adenocarcinoma (~15 %), colorectal adenocarcino
Autor:
Thau F. Ho, Yan Liu, Xinrong Tian, Patrick McDevitt, Michael Butticello, Timothy K. Hart, Kimberly N. Smitheman, David Soong, Jessica L. Schneck, Peter J. Tummino, Christine L. Hann, Glenn S. Van Aller, Yuchen Bai, Nestor O. Concha, Kasparec Jiri, Melissa B. Pappalardi, Christopher L. Carpenter, Mcnulty Kenneth C, Kelly Federowicz, Jeffrey D. Carson, William H. Miller, Johnson Neil W, Chandrashekhar D. Kamat, Rouse Meagan B, Charles F. McHugh, Michael T. McCabe, Ryan G. Kruger, Dashyant Dhanak, Helai P. Mohammad, Michelle Crouthamel, Yan Degenhardt, William G. Bonnette, Shelby A. Gorman
Publikováno v:
Cancer cell. 28(1)
SummaryEpigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic machinery have become a major focus for targeted therapies. The current report describes the discovery and biological activity of a cyclopropyl
Autor:
Adel Giaid, Eliot H. Ohlstein, Stephen A. Douglas, Wisam Ramli, Dashyant Dhanak, Julia Pottinger, Nicolas Bousette
Publikováno v:
Peptides. 27:2919-2926
It is now well established that urotensin-II (UII) levels are increased in several cardiovascular diseases. We previously demonstrated that UII and the UII receptor (UT) protein levels are significantly increased in the hearts of both humans and rats
Publikováno v:
Journal of Molecular and Cellular Cardiology. 41:285-295
Expression of urotensin II (UII) is significantly elevated in the hearts of patients with congestive heart failure (CHF). Recent reports have also shown increased plasma levels of UII in patients with CHF, and these levels correlated with the severit
Autor:
Breen Ann L, Lance Ridgers, David G. Tew, Dashyant Dhanak, Arun C. Kaura, Paddy Lavery, George Burton, Andrew West, Dinubhai H. Shah, Richard M. Keenan, Michael G. Darcy
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:3677-3682
A novel class of CMV protease inhibitors based on a benzothiopyran-S,S-dioxide nucleus has been discovered. Enzyme kinetic data supports a reversible mode of inhibition for a representative member of this class, 2-(3-pyridyl-N-oxide)benzothiopyran-4-
Autor:
Dashyant Dhanak, Romain Luc Marie Gosmini, Olena Barbash, Rab K. Prinjha, BaoChau Le, Gopinath Ganji, Kimberly N. Smitheman, Chun-wa Chung, Karen M. Kennedy-Wilson, Nigel J. Parr, Peter D. Craggs, Charles F. McHugh, Lydia V. Sanchez, Peter J. Tummino, Yuchen Bai, Anastasia Wyce, Susan Korenchuk, Kurt R. Auger, Michael T. McCabe
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72967 (2013)
PLoS ONE
PLoS ONE
BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis. Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in p
Autor:
Stephan, Beck, Bradley E, Bernstein, Robert M, Campbell, Joseph F, Costello, Dashyant, Dhanak, Joseph R, Ecker, John M, Greally, Jean-Pierre, Issa, Peter W, Laird, Kornelia, Polyak, Benjamin, Tycko, Peter A, Jones, Jun, Wang
Publikováno v:
Cancer Research
Recent whole-genome sequencing of thousands of human cancers has uncovered an unexpectedly large number of mutations in genes, which control the epigenome. Many of these recurrent mutations are in epigenetic writers (e.g., EZH2, DNMT3a), readers (BRD
Autor:
Duke M. Fitch, Stephen Schauer, Steven D. Knight, Zhengping Wang, Michael N. Zimmerman, Kurt R. Auger, Roman Sakowicz, Dashyant Dhanak, Han-Jie Zhou, Amita M. Chaudhari, Carrie E. Aroyan, Jeffrey T. Finer, Deping Chai, Jeffrey R. Jackson, Lance Ridgers, Luke W. Ashcraft, Seyed Ahmed, Kenneth Wood, Erin D. Hugger, Jennifer Kuo Chen Huang, Melchor V. Marin, John D. Elliott, Andrew Mcdonald, Cynthia A. Parrish, David Sutton, Ramesh Baliga, Mariela Colón, Lisa D. Belmont, Carla A. Donatelli, Nicholas D. Adams, Joelle Lorraine Burgess, Hong Jiang, Rosanna Tedesco, Bing Yao, Jianchao Wang, Kevin J. Duffy, Gustave Bergnes, Xiangping Qian, Chiu-Mei Sung, David J. Morgans, Robert A. Copeland, Bradley P. Morgan, Michael G. Darcy, Jeffrey D. Carson, Latesh Lad, Ken A. Newlander, Lusong Luo, Daniel W. Pierce, Schmidt Stanley J
Publikováno v:
ACS medicinal chemistry letters. 1(1)
Inhibition of mitotic kinesins represents a novel approach for the discovery of a new generation of anti-mitotic cancer chemotherapeutics. We report here the discovery of the first potent and selective inhibitor of centromere-associated protein E (CE
Autor:
Stephen A. Douglas, Adel Giaid, Eliot H. Ohlstein, Ghada S. Hassan, Ewa Rakowski, Dashyant Dhanak
Publikováno v:
Journal of molecular and cellular cardiology. 39(5)
Recent studies have postulated that the vasoactive peptide urotensin II (UII) plays a role in the control of vascular remodeling by inducing smooth muscle proliferation and fibroblast-mediated collagen deposition. The present study examined the expre